Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...

The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults ...

The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 272,850 shares of Nurix common ...

Cybersecurity company SailPoint opened for trading on Thursday, returning to the markets more than two years after it went private.Maximize ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Picture a horse running across an open field, the wind blowing his mane, his hooves stamping into the grassy knoll, eyes on ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...

A research team has revealed that cadmium, a toxic heavy metal, increases the synthesis of hyaluronan in vascular endothelial ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...